CMV-specific immune responses and HLA phenotypes of AIDS patients who develop CMV retinitis. HNRC Group. HIV Neurobehavioral Research Center.
HLA phenotype and immune responses to CMV were studied to determine whether the subset of AIDS patients who developed CMV retinitis were immunogenetically or immunologically predisposed. CMV retinitis develops in approximately 28-35% of AIDS patients and CMV encephalitis develops in 40% of those with retinitis, often leading to death. T-cell proliferation responses to CMV and HIV were assayed prospectively in individuals enrolled in a longitudinal study at the HIV Neurobehavioral Research Center (HNRC) in San Diego. Seventy-three participants, at various stages of disease, have been HLA typed and followed, clinically and immunologically, for up to 5 years. Six HIV infected individuals who eventually developed CMV retinitis, and were assayed prospectively, had a history of low T-cell proliferation to CMV antigens before they were profoundly immunosuppressed. All 10 individuals with CMV retinitis had at least one of three HLA alleles (or combinations): A2B44 (p = 0.02), B51(p = 0.02), or DR7 (p = 0.01) (collective p value = 0.007). Three of the 10 had two or more of these alleles. Of AIDS patients with CD4 counts below 100 and actively at risk for retinitis, 7/15 with A2B44,51, or DR7 have developed retinitis compared to 0/13 without these HLA alleles (relative risk = 23.8). All 4 patients with these alleles who have died, had retinitis. These results suggest that HIV infected individuals with HLA phenotypes A2B44, B51, and DR7 have low T-cell immune responses to CMV and are predisposed to CMV retinitis and encephalitis as immunodeficiency progresses.
Schrier
R D
RD
Department of Pathology, University of California, San Diego, La Jolla 92093.
Freeman
W R
WR
Wiley
C A
CA
McCutchan
J A
JA
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology / Q000276:immunology*; D000914:Antibodies, Viral; D003587:Cytomegalovirus / Q000276:immunology; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000453:epidemiology / Q000276:immunology*; D004198:Disease Susceptibility / Q000276:immunology; D018792:Encephalitis, Viral / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006680:HLA Antigens / Q000032:analysis* / Q000235:genetics; D006801:Humans; D007111:Immunity, Cellular; D011446:Prospective Studies
D000914:Antibodies, Viral; D006680:HLA Antigens